HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
Barbara Seitz-Polski Selected Research
Barbara Seitz-Polski Research Topics
Disease
18
Membranous Glomerulonephritis (Membranous Nephropathy)
01/2022 - 06/2013
8
COVID-19
01/2022 - 01/2020
8
Proteinuria
01/2021 - 12/2014
5
Neoplasms (Cancer)
01/2022 - 05/2014
5
Autoimmune Diseases (Autoimmune Disease)
01/2022 - 06/2013
3
Nephrotic Syndrome (Syndrome, Nephrotic)
01/2021 - 04/2017
2
Nervous System Diseases (Neurological Disorders)
01/2022 - 09/2016
2
Neuromyelitis Optica (Devic's Disease)
01/2022 - 12/2018
1
Multiple Myeloma
01/2022
1
Central Nervous System Vasculitis
01/2022
1
Hematologic Neoplasms (Hematological Malignancy)
01/2022
1
Immune System Diseases (Immune Disorders)
01/2022
1
B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2022
1
Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022
1
Chilblains (Chilblain)
01/2021
1
Cross Infection (Nosocomial Infection)
01/2021
1
Lymphopenia (Lymphocytopenia)
01/2021
1
Melanoma (Melanoma, Malignant)
01/2021
1
Myasthenia Gravis
01/2021
1
Neutropenia
01/2021
1
Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
01/2021
1
Cytokine Release Syndrome
01/2020
1
Infections
01/2020
1
Albuminuria
01/2020
1
Chronic Kidney Failure (Chronic Renal Failure)
04/2017
1
Hidradenitis Suppurativa
01/2017
1
Inflammation (Inflammations)
09/2016
1
Multiple Sclerosis
09/2016
1
Demyelinating Diseases (Demyelinating Disease)
09/2016
1
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
09/2016
1
Kidney Diseases (Kidney Disease)
05/2014
Drug/Important Bio-Agent (IBA)
10
Phospholipase A2 Receptors
IBA
12/2020 - 06/2013
9
Rituximab (Mabthera)
FDA Link
01/2022 - 12/2018
8
Antibodies
IBA
01/2022 - 05/2014
8
Autoantibodies
IBA
12/2020 - 06/2013
5
Antigens
IBA
01/2022 - 05/2014
5
Proteins (Proteins, Gene)
FDA Link
01/2021 - 06/2013
5
Thrombospondins
IBA
12/2020 - 12/2014
5
Epitopes
IBA
01/2020 - 01/2016
4
Biomarkers (Surrogate Marker)
IBA
01/2021 - 09/2016
4
Autoantigens
IBA
12/2020 - 01/2016
3
Biological Products
IBA
01/2022 - 01/2021
3
Interleukin-6 (Interleukin 6)
IBA
01/2022 - 01/2017
3
Vaccines
IBA
01/2022 - 01/2021
2
mRNA Vaccines
IBA
11/2021 - 01/2021
2
Serum Albumin
IBA
01/2021 - 01/2018
2
Interferons
IBA
01/2020 - 01/2020
2
Immunoglobulin G (IgG)
IBA
01/2020 - 12/2014
1
Complement System Proteins (Complement)
IBA
01/2022
1
Neutralizing Antibodies
IBA
01/2022
1
Myelin-Oligodendrocyte Glycoprotein
IBA
01/2022
1
BNT162 Vaccine
IBA
01/2022
1
Interferon-alpha (Interferon Alfa)
IBA
01/2021
1
Nivolumab
IBA
01/2021
1
COVID-19 Vaccines
IBA
01/2021
1
Creatine
IBA
01/2021
1
fibrin fragment D (D-dimer)
IBA
01/2021
1
Aldehyde Reductase (Aldose Reductase)
IBA
12/2020
1
Phosphopyruvate Hydratase (Enolase)
IBA
12/2020
1
Immunologic Factors (Immunomodulators)
IBA
01/2020
1
Immunoglobulin A (IgA)
IBA
01/2020
1
Cytokines
IBA
01/2020
1
Interleukin-8 (Interleukin 8)
IBA
01/2020
1
Creatinine
IBA
01/2020
1
C-Reactive Protein
IBA
01/2017
1
Infliximab (Remicade)
FDA Link
01/2017
1
Interleukin-17 (Interleukin 17)
IBA
09/2016
Therapy/Procedure
2
Drug Therapy (Chemotherapy)
06/2021 - 01/2021
2
Therapeutics
01/2021 - 01/2021
2
Kidney Transplantation
04/2017 - 12/2014
1
Nursing Care
01/2022
1
Patient Isolation
01/2022
1
Length of Stay
01/2021
1
Radiotherapy
01/2021
1
Precision Medicine
01/2020
1
Transplantation
12/2014